Ribomic Inc
TSE:4591
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Ribomic Inc
Net Income (Common)
Ribomic Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Ribomic Inc
TSE:4591
|
Net Income (Common)
-¥814.7m
|
CAGR 3-Years
26%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-8%
|
|
|
SanBio Co Ltd
TSE:4592
|
Net Income (Common)
-¥3.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
-18%
|
|
|
GNI Group Ltd
TSE:2160
|
Net Income (Common)
-¥4.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-21%
|
|
|
PeptiDream Inc
TSE:4587
|
Net Income (Common)
-¥3.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Takara Bio Inc
TSE:4974
|
Net Income (Common)
-¥7.2B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
Oncolys Biopharma Inc
TSE:4588
|
Net Income (Common)
-¥2.1B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-9%
|
|
Ribomic Inc
Glance View
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. The company is headquartered in Minato-Ku, Tokyo-To and currently employs 25 full-time employees. The company went IPO on 2014-09-25. Its drug discovery business is divided into self discovery and co-discovery divisions. Self Drug Discovery division develops aptamer and licenses and out the results to pharmaceutical companies. The Co-Discovery division earns the research expenses paid by the alliance partner for the shared part of co-discovery business with alliance pharmaceutical companies researching aptamer pharmaceutical.
See Also
What is Ribomic Inc's Net Income (Common)?
Net Income (Common)
-814.7m
JPY
Based on the financial report for Dec 31, 2025, Ribomic Inc's Net Income (Common) amounts to -814.7m JPY.
What is Ribomic Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
-8%
Over the last year, the Net Income (Common) growth was 15%. The average annual Net Income (Common) growth rates for Ribomic Inc have been 26% over the past three years , 5% over the past five years , and -8% over the past ten years .
